pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal breast cancer patients. Age oestrogen (ER) and progesterone (PR) receptor status are accurately considered to select patients for hormonal treatment. However, additional markers are needed. By immunohistoche...

Descripción completa

Detalles Bibliográficos
Autores principales: Soubeyran, I., Quénel, N., Coindre, J. M., Bonichon, F., Durand, M., Wafflart, J., Mauriac, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077113/
https://www.ncbi.nlm.nih.gov/pubmed/8855985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077113/
https://www.ncbi.nlm.nih.gov/pubmed/8855985

Ejemplares similares